Antioxidants and beneficial microvascular effects: Is this the remedy?

Hypertension

Volumn 55, Issue 6, 2010, Pages 1310-1311

  Ferri, Claudio ^a   Grassi, Davide ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MELATONIN; NITRIC OXIDE; PYCNOGENOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ATHEROMA; BIOAVAILABILITY; BIOLOGICAL ACTIVITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIET SUPPLEMENTATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HYPERTENSION; LIPID PEROXIDATION; LIPID STORAGE; NONHUMAN; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FLAVONOIDS; HUMANS; HYPERTENSION; MELATONIN; MICROCIRCULATION; NITRIC OXIDE; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 77952957580     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.152165     Document Type: Note

References (10)

1. Rodgers A, Ezzati M, Vander Hoorn S, Lopez AD, Lin RB, Murray CJ, for the Comparative Risk Assessment Collaborating Group. Distribution of major health risks: findings from the Global Burden of Disease Study. PLoS Med. 2004;1:e27.
2. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285-1295.
3. Griendling KK, Fitzgerald GA. Oxidative stress and cardiovascular injury: part II-animal and human studies. Circulation. 2003;108:2034-2040.
4. Landmesser U, Harrison DG. Oxidative stress and vascular damage in hypertension. Coron Artery Dis. 2001;12:455-461.
5. Paulis L, S?imko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res. 2007; 56:671-684.
6. Rohdewald P. A review of the French maritime pine bark extract (Pyc-nogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. 2002;40:158-168.
7. Rezzani R, Porteri E, De Ciuceis C, Bonomini F, Rodella LF, Paiardi S, Boari GEM, Platto C, Pilu A, Avanzi D, Rizzoni D, Agabiti Rosei E. Effects of melatonin and Pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension. 2010;55:1373-1380.
8. Anwar MM, Meki AR, Rahma HH. Inhibitory effects of melatonin on vascular reactivity: possible role of vasoactive mediators. Comp Biochem Physiol C Toxicol Pharmacol. 2001;130:357-367.
9. Hussein MR, Ahmed OG, Hassa AF, Ahmed MA. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int J Exp Pathol. 2007;88:19-29.
10. Grassi D, Desideri G, Croce G, Tiberti S, Aggio A, Ferri C. Flavonoids, vascular function and cardiovascular protection. Curr Pharm Des. 2009; 15:1072-1084.